Strong half for Evotec as revenue jumps thanks to Big Pharma collabs

Evotec has posted a 37% sales jump in the first half of 2016 with its income bumped up to €75.7 million ($84.1 million) as it reaps the benefits of its collabs as well as its core business.

The German company, which is a hybrid CRO-cum-drug discovery firm, also saw its research receipts grow for the first half, up by 6% to €9 million as it ramps up the projects in its portfolio.

A fair chunk of its growth came from hitting a number of R&D milestones in the year, including those with Bayer, Boehringer Ingelheim and Padlock (now owned by Bristol-Myers Squibb [$BMY]).

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

But even when these milestones, upfronts and licenses are taken out of the mix, Evotec's base revenues still hit €68.5 million, an increase of 35% over the same period of the previous year.

EVT Execute, Evotec's CRO division, also saw sales reach €79.8 million in the first half--an increase of 35% compared with 2015 figures.

The company has also signed a number of new deals over the past few months, including with a U.K. antibiotics group to help reverse resistance to older meds, as well as signing a pact to gain access to the hot ticket CRISPR tech.

It also launched its first spinoff, Topas Therapeutics GmbH, that will specialize in the field of nanoparticle-based therapeutics to treat immunological disorders.

- check out the release

Related Articles:
Evotec evolves as it announces first-ever spinoff and new business model
Evotec posts 50% growth with a big year in sight

Read more on

Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.